The MARVEL Project

MARVEL mission is to combine and implement reversible capturing and peptide science, towards the first and best performing ever affinity-based technology for scalable small EV (<200 nm) isolation. By introducing membrane-sensing peptides as novel affinity ligands, the project aims to overcome limitations of traditional antibody-based methods and enable efficient, reversible capture and release of structurally intact EVs across medium to large sample volumes. The scalable and modular platform will be demonstrated in relevant therapeutic and diagnostic applications, supporting the advancement of EV-based research and clinical workflows.

HansaBioMed took the lead in component and system integration for different scales based on the designed and optimized probes for EV isolation with specifications set for various biological samples.

HansaBioMed Life Sciences, Amires, CNR-SCITEC, CNR-ITM, Istituto Cardiocentro Ticino, Paperdrop Diagnostics, Vita-Salute San Raffaele University